Clinical trials: sponsored by CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Overweight or Obesity
A Single Ascending Dose and Multiple Ascending Doses Study of SYH2082 Injection in Healthy Participants
To evaluate the safety and tolerability of single dose and multiple doses of SYH2082 Injection in healthy participants.
- Trial name
- NCT07532655
- Testing
- SYH2082 Injection
- Where
- Australia
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Healthy Participants
Evaluation of Bioequivalence and Food Effect of a New Strength Formulation of Ammoxetine Hydrochloride Enteric-coated Tablets in Healthy Participants.
Evaluation of Bioequivalence and Food Effect of a New Strength Formulation of Ammoxetine hydrochloride Enteric-coated Tablets in Healthy Participants.The study is composed of 2 parts.
- Trial name
- NCT07756996
- Testing
- Ammoxetine hydrochloride Enteric-coated Tablets(new formulation), Ammoxetine hydrochloride Enteric-coated Tablets(Phase III formulation)
- Where
- China
- Volunteers
- 62 people, healthy volunteers welcome
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Healthy Participants, Participants With Mild Hepatic Impairment
A Phase I Clinical Trial to Evaluate the Pharmacokinetic and Safety of Ammoxetine Hydrochloride Enteric-Coated Tablets in Participants With Mild Hepatic Impairment, Moderate Hepatic Impairment, and Normal Liver Function
Use these resources to provide understandable information about this study to patients, families, and health care providers:This study is a multi-center, non-randomized, open-label, parallel-group, multiple-dose Phase I clinical…
- Conditions
- Healthy Participants, Participants With Mild Hepatic Impairment, Participants With Moderate Hepatic Impairment
- Trial name
- NCT07694843
- Testing
- ammoxetine hydrochloride enteric-coated tablets
- Where
- China
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Healthy Participants, Participants With Moderate Renal Impairment
A Phase I Clinical Trial to Evaluate the Pharmacokinetic Characteristics of Ammoxetine Hydrochloride Enteric-Coated Tablets in Participants With Moderate Renal Impairment and Normal Renal Function
This study is a single-center, non-randomized, open-label, parallel-group, multiple-dose Phase I clinical trial evaluating the pharmacokinetic characteristics of ammoxetine hydrochloride enteric-coated tablets in participants…
- Trial name
- NCT07694869
- Testing
- ammoxetine hydrochloride enteric-coated tablets
- Where
- China
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Healthy Participants
A Clinical Trial to Evaluate the Effect of Food on the Pharmacokinetics of Ammoxetine Hydrochloride Enteric-coated Tablets in Healthy Subjects
This study is a single-dose, randomized, open-label, three-sequence, three-period crossover clinical trial to evaluate the effect of high-fat and low-fat meals on the pharmacokinetics of ammoxetine hydrochloride enteric-coated…
- Trial name
- NCT07508462
- Testing
- Ammoxetine hydrochloride enteric-coated tablets
- Where
- China
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Healthy Participants
Food-effect Study of Ammoxetine Hydrochloride Enteric-coated Tablets
This study is a single-center, randomized, open-label, two-period crossover design to evaluate the effect of food on the pharmacokinetic profile of ammoxetine hydrochloride enteric-coated tablets.
- Trial name
- NCT07508501
- Testing
- Ammoxetine hydrochloride enteric-coated tablets
- Where
- China
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Healthy Participants
A Single Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of SYH2085
Randomized, double-blind and placebo-controlled study to assess the safety, tolerability and pharmacokinetics of single ascending doses of SYH2085 and its food effect in China healthy adult participants.
- Trial name
- NCT07412353
- Testing
- SYH2085
- Where
- China
- Volunteers
- 74 people, healthy volunteers welcome
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Acromegaly
A Single-dose Study of Octreotide Injection in Healthy Adult Subjects
This is a single-centre, single-dose, dose-escalation, placebo and positive drug-controlled Phase I clinical study in healthy Chinese subjects to evaluate the safety, tolerability, pharmacokinetic and pharmacodynamic profile of…
- Trial name
- NCT05761431
- Testing
- SYHX2008 injection, Octreotide Acetate Microspheres for Injection injection, Sandostatin ® injection
- Where
- China
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
SARS-CoV-2
A Study of SARS-CoV-2 mRNA Vaccine (SYS6006) in Chinese Healthy Adults Aged 18 -59 Years.
This is a phase I, randomized, observer-blinded, placebo-controlled and dose-escalation clinical trial to evaluate the safety, tolerability, immunogenicity and immune persistence of SYS6006 (SARS-CoV-2 mRNA Vaccine) in 18-59 year…
- Trial name
- NCT05354089
- Testing
- 20 μg dose of SYS6006, 30 μg dose of SYS6006
- Where
- 2 sites in China
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
SARS-CoV-2
A Study of SARS-CoV-2 mRNA Vaccine (SYS6006) in Chinese Healthy Older Adults.
This is a phase I, randomized, observer-blinded, placebo-controlled and dose-escalation clinical trial to evaluate the safety and preliminary immunogenicity of SARS-CoV-2 mRNA Vaccine (SYS6006) in Chinese healthy adults aged 60…
- Trial name
- NCT05354063
- Testing
- 20 μg dose of SYS6006, 30 μg dose of SYS6006
- Where
- 2 sites in China
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
SARS-CoV-2 Infection
A Study of SARS-CoV-2 mRNA Vaccine (SYS6006) in Chinese Healthy Participants Aged 18 Years or More
This is a phase 2, randomized, observer-blinded, placebo-controlled clinical study to evaluate the immunogenicity and safety of SARS-CoV-2 mRNA Vaccine (SYS6006）in healthy participants aged 18 or more.
- Trial name
- NCT05439824
- Testing
- SYS6006 20 μg, SYS6006 30 μg
- Where
- 2 sites in China
- Volunteers
- 450 people, healthy volunteers welcome
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Hepatic Impairment
A Study to Evaluate the Pharmacokinetics and Safety of DBPR108 in Subjects With Hepatic Impairment
This is an open-label, single-dose study to evaluate the pharmacokinetics and safety of DBPR108 in subjects with mild or moderate hepatic impairment (HI) compared to the matched control subjects with normal hepatic function.
- Trial name
- NCT04859426
- Testing
- DBPR108 tablets
- Where
- China
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Healthy Subjects
A Study to Evaluate the Effect of Different Meal Types on the Pharmacokinetics of DBPR108 in Healthy Subjects
This is an open-label, randomized, three-period, crossover, single-dose study to evaluate the effects of a low-fat meal and a standard meal on the pharmacokinetics of DBPR108 and the safety and tolerability of DBPR108 under…
- Trial name
- NCT05150626
- Testing
- DBPR108 tablets
- Where
- China
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Healthy Male Subjects
A Mass Balance and Biotransformation Study of [14C]SKLB1028 in Chinese Healthy Male Subjects
This is a single-centre, open-label, mass balance and biotransformation study in healthy male subjects utilising a single oral dose of [14C] SKLB1028.
- Trial name
- NCT05369858
- Testing
- [14C] SKLB1028
- Where
- China
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Renal Impairment
A Study to Evaluate the Pharmacokinetics and Safety of DBPR108 in Subjects With Renal Impairment
This is an open-label, single-dose study to evaluate the pharmacokinetics and safety of DBPR108 in subjects with mild, moderate, severe renal impairment and subjects with kidney failure compared to the matched control subjects…
- Trial name
- NCT04859439
- Testing
- DBPR108 tablets
- Where
- China
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Healthy Subjects
A Study to Evaluate Relative Bioavailability and Food-Effect of HA121-28 Tablet B in Healthy Subjects
The study will be divided into 2 parts. The first part is a relative bioavailability study of HA121-28 tablet A and HA121-28 tablet B, and the second part is a food effect study of HA121-28 tablet B.
- Trial name
- NCT05072535
- Testing
- HA121-28 tablet B, HA121-28 tablet A
- Where
- China
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Healthy Subjects
A Study to Evaluate the Drug-drug Interactions (DDIs) of DBPR108 With Warfarin Sodium, Digoxin, Probenecid in Healthy Subjects
This is a three-part, single-center, open-label phase I clinical study to characterize the DDIs potential of DBPR108 with Warfarin sodium, Digoxin, or Probenecid in healthy subjects.
- Trial name
- NCT05045313
- Testing
- Warfarin sodium tablets, Digoxin tablet, Probenecid tablets
- Where
- China
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Healthy Male Subjects
Mass Balance and Biotransformation Study of [14C]DBPR108 in Human
This is a single-center, open-label phase I clinical study to evaluate the mass balance and biotransformation pathways of [14C]DBPR108 in Chinese healthy adult male subjects, to reveal the overall pharmacokinetic characteristics…
- Trial name
- NCT05072028
- Testing
- [14C]DBPR108
- Where
- China
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Healthy Subjects
A Dose Escalation and Food Effect Study of SKLB1028 in Healthy Subjects
The purpose of this study was to explore the safety, tolerability and pharmacokinetics (PK) of single ascending oral doses of SKLB1028 in healthy subjects. This study has also explored the effect of food on the PK of SKLB1028.
- Trial name
- NCT05109663
- Testing
- SKLB1028
- Where
- China
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Healthy Subjects
A Study to Investigate the Drug-drug Interactions (DDIs) Between SKLB1028 and Midazolam in Healthy Subjects
This is a single-center, open-label phase I clinical study to investigate the effect of SKLB1028 on the pharmacokinetics of Midazolam and its metabolite 1'-OH-midazolam in healthy subjects.
- Trial name
- NCT05070195
- Testing
- SKLB1028, Midazolam
- Where
- China
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.